Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 4;14(5):1336.
doi: 10.3390/cancers14051336.

Metformin Intervention-A Panacea for Cancer Treatment?

Angelika Buczyńska  1 , Iwona Sidorkiewicz  1 , Adam Jacek Krętowski  1   2 , Monika Zbucka-Krętowska  3 , Agnieszka Adamska  2
Affiliations
Review

Metformin Intervention-A Panacea for Cancer Treatment?

Angelika Buczyńska et al. Cancers (Basel). .

Abstract

The molecular mechanism of action and the individual influence of various metabolic pathways related to metformin intervention are under current investigation. The available data suggest that metformin provides many advantages, exhibiting anti-inflammatory, anti-cancer, hepatoprotective, cardioprotective, otoprotective, radioprotective, and radio-sensitizing properties depending on cellular context. This literature review was undertaken to provide novel evidence concerning metformin intervention, with a particular emphasis on cancer treatment and prevention. Undoubtedly, the pleiotropic actions associated with metformin include inhibiting inflammatory processes, increasing antioxidant capacity, and improving glycemic and lipid metabolism. Consequently, these characteristics make metformin an attractive medicament to translate to human trials, the promising results of which were also summarized in this review.

Keywords: anti-cancer; antioxidant; metformin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA-based flow diagram of the meta-analysis process performed [194,198].
See this image and copyright information in PMC

References

    1. Sanchez-Rangel E., Inzucchi S.E. Metformin: Clinical use in type 2 diabetes. Diabetologia. 2017;60:1586–1593. doi: 10.1007/s00125-017-4336-x. - DOI - PubMed
    1. Graham G.G., Punt J., Arora M., Day R.O., Doogue M.P., Duong J.K., Furlong T.J., Greenfield J.R., Greenup L.C., Kirkpatrick C., et al. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 2011;50:81–98. doi: 10.2165/11534750-000000000-00000. - DOI - PubMed
    1. Foretz M., Guigas B., Bertrand L., Pollak M., Viollet B. Metformin: From mechanisms of action to therapies. Cell Metab. 2014;20:953–966. doi: 10.1016/j.cmet.2014.09.018. - DOI - PubMed
    1. Sugiyama S., Jinnouchi H., Hieshima K., Kurinami N., Jinnouchi K. Type 2 diabetes remission and substantial body weight reduction achieved with metformin and a sodium-glucose cotransporter 2 inhibitor. Cureus. 2020;12:e7110. doi: 10.7759/cureus.7110. - DOI - PMC - PubMed
    1. Soukas A.A., Hao H., Wu L. Metformin as anti-aging therapy: Is it for everyone? Trends Endocrinol. Metab. 2019;30:745–755. doi: 10.1016/j.tem.2019.07.015. - DOI - PMC - PubMed

LinkOut - more resources